Abstract
BackgroundDisease-modifying therapeutic options are needed for patients with osteoarthritis (OA). Zoledronic acid (ZA) is a potential option as it reduced both knee pain and knee bone marrow lesion (BML) size...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
